NRx Pharmaceuticals is a clinical stage pharmaceutical company that is developing, through its wholly owned operating subsidiary, NeuroRx, NRX-100 and NRX-101, the first oral therapeutic for the treatment of Bipolar Depression in patients with Acute Suicidal Ideation and Behavior (ASIB) and Sub-Acute Suicidal Ideation and Behavior (“SSIB”). NRX-100 and NRX-101 were developed based upon 30 years of basic science and clinical expertise contributed by Dr. Daniel Javitt, MD, PhD, related to the role of the brain’s N-methyl-D-aspartate (“NMDA”) receptor in regulating human thought processes in general and in regulating depression and suicidality. The NRX-100 and NRX-101 investigational therapy begins with a single dose of ketamine (NRX-100), a Food & Drug Administration (“FDA”) approved anesthetic, followed by approximately six weeks of daily oral NRX-101. NRX-101 is being developed as a rapid-onset and sustained treatment for bipolar depression with ASIB and SSIB. NRX-101 combines d-Cycloserine, a NMDA receptor modulator, and lurasidone, a 5-HT2a receptor antagonist.
Company profile
Ticker
NRXP
Exchange
Website
CEO
Richard S. Ackerman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Big Rock Partners Acquisition Corp.
SEC CIK
NRXP stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEF 14A
Definitive proxy
11 Mar 24
8-K
Other Events
6 Mar 24
8-K
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
28 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
Transcripts
NRXP
Earnings call transcript
2023 Q3
14 Nov 23
NRXP
Earnings call transcript
2023 Q2
14 Aug 23
NRXP
Earnings call transcript
2023 Q1
16 May 23
NRXP
Earnings call transcript
2022 Q4
30 Mar 23
NRXP
Earnings call transcript
2022 Q3
14 Nov 22
NRXP
Earnings call transcript
2022 Q2
15 Aug 22
NRXP
Earnings call transcript
2022 Q1
16 May 22
NRXP
Earnings call transcript
2021 Q4
31 Mar 22
NRXP
Earnings call transcript
2021 Q3
16 Nov 21
NRXP
Earnings call transcript
2021 Q2
17 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.90 mm | 8.90 mm | 8.90 mm | 8.90 mm | 8.90 mm | 8.90 mm |
Cash burn (monthly) | 2.02 mm | 778.92 k | 1.94 mm | 2.78 mm | 1.52 mm | 2.23 mm |
Cash used (since last report) | 11.39 mm | 4.39 mm | 10.91 mm | 15.64 mm | 8.57 mm | 12.57 mm |
Cash remaining | -2.49 mm | 4.51 mm | -2.00 mm | -6.74 mm | 332.58 k | -3.67 mm |
Runway (months of cash) | -1.2 | 5.8 | -1.0 | -2.4 | 0.2 | -1.6 |
Institutional ownership, Q2 2023
12.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 6 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 4.80 bn |
Total shares | 11.14 mm |
Total puts | 4.50 k |
Total calls | 105.80 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 5.64 mm | $2.73 bn |
Vanguard | 1.48 mm | $714.69 mm |
Sabby Management | 699.73 k | $338.32 mm |
Big Rock Partners Sponsor | 655.57 k | $15.90 mm |
BRAC Lending | 590.44 k | $14.32 mm |
CVI | 483.57 k | $233.81 mm |
Geode Capital Management | 378.67 k | $183.09 mm |
BLK Blackrock | 290.71 k | $140.56 mm |
RY Royal Bank Of Canada | 171.23 k | $83.00 mm |
Bridgeway Capital Management | 160.70 k | $77.70 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Aug 23 | Aaron Gorovitz | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 0.3199 | 35,000 | 11.20 k | 105,000 |
30 Aug 23 | Hurvitz Chaim | Common Stock, par value $0.001 per share | Buy | Acquire P | No | No | 0.2875 | 70,000 | 20.13 k | 570,000 |
23 Aug 23 | Javitt Jonathan C | Common Stock | Buy | Acquire P | No | No | 0.33 | 100,000 | 33.00 k | 446,332 |
News
NRx Pharmaceuticals To Distribute Shares of HOPE Therapeutics And Royalty Rights On Ketamine Sales To Existing NRx Shareholders
18 Mar 24
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Mar 24
Nasdaq Surges Over 1%; Blade Air Mobility Shares Plummet
12 Mar 24
Dow Gains 100 Points; US Inflation Rate Rises To 3.2% In February
12 Mar 24
Press releases
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
12 Mar 24
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
11 Mar 24
Trial Endpoint Reached for First Suicidal Bipolar Depression, Chronic Pain and PTSD Drug; Agreement with Partners Can Provide up to $329 Million and Royalties: NRx Pharmaceuticals (Nasdaq: NRXP)
4 Mar 24
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
4 Mar 24
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
1 Mar 24